CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines
Authors
Atsushi Mizokami
Bargou
+42 more
Burke
Chun
Cornwell
Drukman
Duan
Dumontet
Enokida
Evan T. Keller
Ferlini
Fulton
Furukawa
Goto
Hopper-Borge
Jemal
Jian Zhang
Kiminori Mamiya
Leukert
Li
Lin
Masashi Takeda
Mikio Namiki
Mizokami
Nakayama
Obasaju
Ohga
Orr
Oudard
Padar
Petrylak
Ranganathan
Ranganathan
Song
Tada
Tannock
Teraishi
Ueda
Villeneuve
Vogl
Yamanaka
Yamanaka
Yang
You Qiang Li
Publication date
1 January 2007
Publisher
'Wiley'
Doi
Cite
Abstract
BACKGROUND Although paclitaxel is used for hormone-resistant prostate cancer, relapse definitely occurs later. Details of the molecular mechanism responsible for paclitaxel- resistance remain unclear. METHODS We established paclitaxel-resistant cells, DU145-TxR and PC-3-TxR from parent DU145 and PC-3. To characterize these cells, we examined cross-resistance to other anticancer drugs. Expression of several potential genes that had been related to drug-resistance was compared with parent cells by RT-PCR and Western blotting. Methylation analysis of multiple drug resistance (MDR1) promoter was carried out using bisulfite-modified DNA from cell lines. Knockdown experiments using small interfering RNA (siRNA) were also performed to confirm responsibility of drug-resistance. Finally, cDNA microarray was performed to quantify gene expression in PC-3 and PC-3-TxR cells. RESULTS The IC 50 for paclitaxel in DU145-TxR and PC-3-TxR was 34.0- and 43.4-fold higher than that in both parent cells, respectively. Both cells showed cross-resistance to some drugs, but not to VP-16 and cisplatin. Methylation analysis revealed that methylated CpG sites of MDR1 promoter in DU145 and PC-3 cells were demethylated in DU145-TxR cells, but not in PC-3-TxR cells. Knockdown of P-glycoprotein (P-gp), which was up-regulated in resistant cells, by MDR-1 siRNA restored paclitaxel sensitivity in DU145-TxR but not in PC-3-TxR, indicating that up-regulation of P-gp was not always main cause of paclitaxel-resistance. Microarray analysis identified 201 (1.34%) up-regulated genes and 218 (1.45%) out of screened genes in PC-3-TxR. CONCLUSIONS Our data will provide molecular mechanisms of paclitaxel-resistance and be useful for screening target genes to diagnose paclitaxel sensitivity. Prostate 67: 955–967, 2007. © 2007 Wiley-Liss, Inc.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/56002/1/20581_ftp.pd
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
Last time updated on 01/04/2019
Kanazawa University Repository for Academic Resources
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:kanazawa-u.repo.nii.ac.jp:...
Last time updated on 06/05/2019
Kanazawa University Repository for Academic Resources
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:kanazawa-u.repo.nii.ac.jp:...
Last time updated on 06/05/2019
Deep Blue Documents at the University of Michigan
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:deepblue.lib.umich.edu:202...
Last time updated on 25/05/2012